venetoclax

May 28, 2019July 1, 2019

Preclinical Study Uncovers Resistance Mechanisms to Lymphoma Therapy and Potential Way to Overcome Them

News

Lymphoma cells can become resistant to therapy as they acquire novel genetic mutations, but a new study has found that they can also become resistant as they reprogram which genes ... Read more

May 17, 2019

FDA Approves Venclexta-Gazyva Combo for Untreated CLL/SLL Patients

News

The U.S. Food and Drug Administration (FDA) has approved the double combination therapy of Venclexta (venetoclax) and Gazyva (obinutuzumab) for the treatment of adults with newly diagnosed chronic lymphocytic leukemia ... Read more

September 18, 2018

Verastem Launches Phase 1/2 Trial to Evaluate Duvelisib-Venclexta Combo in CLL/SLL Patients

News

Verastem Oncology has dosed the first patient in its Phase 1/2 trial testing a combination of duvelisib and Venclexta (venetoclax) in patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) who failed ... Read more

August 2, 2018

Venclexta Triple Combo in NHL Patients Produces Long-lasting Responses in Phase 1 Trial

News

A combination of Venclexta (venetoclax), bendamustine, and Rituxan (rituximab) is tolerable and produces long-lasting responses in patients with relapsed or refractory non-Hodgkin’s lymphoma (NHL), according to a Phase 1 trial. The study, “Venetoclax, bendamustine, ... Read more

November 30, 2017

Leukemia & Lymphoma Society Invests $46M in Research Funding Worldwide

News

As part of its comprehensive research investment program, the Leukemia & Lymphoma Society (LLS) recently committed $46 million to fund the most innovative science looking for cures for blood cancers at ... Read more

April 22, 2016April 22, 2016

Cyclacel Releases Promising Preclinical Data on Potential B-Cell Lymphoma Drug, Is Enrolling Patients for Phase 1 Study

News

Cyclacel Pharmaceuticals disclosed promising preclinical results of its drug candidate, CYC065, for the treatment of B-cell lymphoma in a poster presentation at the recent American Association for Cancer Research (AACR) annual meeting ... Read more

April 14, 2016April 14, 2016

LLS Welcomes FDA Approval of Venclexta to Treat Certain Chronic Lymphocytic Leukemias

News

The Leukemia & Lymphoma Society (LLS) welcomed the recent approval of Venclexta (venetoclax) to treat people with a severe form of chronic lymphocytic leukemia (CLL). The drug, whose development and testing the LLS supported, ... Read more

September 1, 2015September 1, 2015

Phase II Study of Investigational Medicine Venetoclax Meets Primary Endpoint With Positive Results

News

Genentech in partnership with AbbVie Pharmaceuticals and the Leukemia & Lymphoma Society (LLS), recently announced positive results from a Phase 1 clinical trial for venetoclax, an investigational therapy to treat patients with ... Read more

June 12, 2015June 12, 2015

AbbVie Presents Data On Its Oncology Pipeline

News

AbbVie has recently announced recent data on its investigational hematological malignancy medicines will be presented during the 20th European Hematology Association Annual Congress (EHA), June 11 and 14, Vienna. The oral presentation will include results regarding ... Read more